<DOC>
	<DOCNO>NCT00040534</DOCNO>
	<brief_summary>The purpose study determine safety tolerability oral Farnesyl Protein Transferase Inhibitor ( SCH 66336 ) give combination Gemcitabine Cisplatin patient advance cancer .</brief_summary>
	<brief_title>Safety Tolerability Study Farnesyl Protein Transferase Inhibitor Combination With Gemcitabine Cisplatin Advanced Cancer ( Study P01499 ) ( TERMINATED )</brief_title>
	<detailed_description />
	<criteria>Advanced cancer treatment available would reasonable chance disease palliation cure Age great equal 18 . SWOG performance Status le equal 2 . Meets protocol requirement specify laboratory value . Written inform consent cooperation patient . Prior treatment FPTI Knowledge intracranial metastasis carcinomatous meningitis . Poor medical risk nonmalignant systemic disease uncontrolled active infection . Medical condition would interfere take oral medication . Significant uncontrolled diarrhea . Chemotherapy , radiotherapy major surgery within 4 week ; full recovery prior treatment . Concomitant use CYP3A inhibitors/inducers per protocol . Known HIV positivity AIDSrelated illness . Pregnant nursing woman . Men woman childbearing potential use effective method contraception . Concurrent chemotherapy , hormonal therapy , radiotherapy immunotherapy . QTc prolongation ( &gt; 440 msec ) baseline . Patients previous highdose therapy require stem cell rescue bone marrow transplant , irradiation &gt; 30 % bone marrowcontaining area . Patients receive MitomycinC nitrosoureas .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Advanced Cancer</keyword>
</DOC>